ReviewInfectious medicine2026
Nipah virus and the lessons of COVID-19: are we prepared for the next pandemic threat?
Review in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has exposed profound and persistent weaknesses in global preparedness, including fragmented surveillance systems, governance failures, inequitable access to countermeasures, and erosion of public trust. Although SARS-CoV-2 has dominated global attention, other high-consequence zoonotic pathogens with pandemic potential have remained comparatively neglected. Among these, the Nipah virus (NiV) represents a particularly serious threat, characterized by high case-fatality rates, zoonotic spillover from wildlife reservoirs, documented human-to-human transmission, and the absence of licensed vaccines or specific antiviral therapies. This narrative review synthesizes and contextualizes existing evidence on the NiV through the lens of lessons learned during the COVID-19 pandemic. Drawing on epidemiological data, outbreak experience, and global health policy literature, this review examines the key dimensions of preparedness, including surveillance and diagnostics, laboratory and health-system capacity, vaccine and therapeutic development, emergency governance, ethical decision-making, and the operationalization of One Health approaches, with particular attention to low- and middle-income and fragile settings. The review highlights that despite scientific advances achieved during COVID-19, preparedness for the NiV remains limited and uneven. Persistent gaps in integrated surveillance at human-animal-environment interfaces, constrained laboratory capacity, insufficient investment in countermeasures, fragmented governance, and enduring global inequities threaten timely detection and containment. The NiV should therefore be understood not as an isolated regional concern, but as a warning signal for future "Disease X" scenarios, underscoring the urgent need to translate COVID-19 lessons into sustained, equitable, and multisectoral pandemic preparedness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.